Leerink Partners Upgrades Rhythm Pharmaceuticals' Earnings Outlook

Summary

Leerink Partners’ analysts have set expectations for Rhythm Pharmaceuticals’ earnings in the fourth quarter of 2026, predicting earnings per share (EPS) of $0.62. The company currently has a consensus full-year EPS estimate of $4.32. Several analysts have raised the stock’s target price, with Bank of America and Stifel Nicolaus setting a target price of $95.00. Rhythm Pharmaceuticals has a market capitalization of $5.67 billion, and its current stock price is $89.15, with a 1-year high of $94.80. The stock has received a ‘buy’ rating from most analysts. Market Beat

Impact Analysis

The event is classified at the ‘Company Level’ as it pertains directly to Rhythm Pharmaceuticals and its expected financial performance. The positive earnings forecast from Leerink Partners suggests strong anticipated financial performance for the company, which could attract further investor interest and potentially lead to stock price appreciation. Supporting this outlook, the company has recently announced a public offering of $150 million in common stock, which although might initially dilute existing shares, indicates potential for growth and expansion. Reuters Rhythm Pharmaceuticals is also noted for having a healthy balance sheet with net cash, reducing financial risks related to debt. Simplywall Analysts have been optimistic, with Oppenheimer and HC Wainwright raising their target prices and maintaining positive ratings, reinforcing a favorable sentiment around the stock. Market Beat However, it is noted that despite these positive developments, Rhythm Pharmaceuticals is not listed among the top recommended stocks by some analysts, indicating that there might be better opportunities elsewhere according to certain market analyses. Market Beat+ 2 Investors may view the current target prices and positive ratings as opportunities to invest in this stock, potentially ahead of broader market recognition.